| NOTE 17:- | ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS |
Year ended December 31, | ||||||||||||||
| 2017 | 2016 | 2015 | ||||||||||||
| USD in thousands | ||||||||||||||
| a. | Research and development expenses: | |||||||||||||
| Wages and related expenses | $ | 321 | $ | 195 | $ | 47 | ||||||||
| Share-based payment | 103 | 100 | 2 | |||||||||||
| clinical studies | 511 | - | - | |||||||||||
| Research & preclinical studies | 362 | 387 | 176 | |||||||||||
| Chemistry & formulations | 330 | 18 | 8 | |||||||||||
| Regulatory and other expenses | 276 | 40 | 7 | |||||||||||
| 1,943 | 740 | 240 | ||||||||||||
| b. | General and administrative expenses: | |||||||||||||
| Wages and related expenses | 808 | 399 | 363 | |||||||||||
| Share-based payment | 759 | 201 | 136 | |||||||||||
| Professional and directors fee | 1,007 | 495 | 557 | |||||||||||
| Investor relations and business expenses | 871 | - | - | |||||||||||
| Office maintenance, rent and other expenses | 211 | 58 | 226 | |||||||||||
| Regulatory expenses | 80 | 28 | 20 | |||||||||||
| Business development | 74 | 87 | 61 | |||||||||||
| 3,810 | 1,268 | 1,363 | ||||||||||||
| c. | Other (income) expenses: | |||||||||||||
| Share-based payment | - | 26 | 1,005 | |||||||||||
| Change in liability to the INATI | - | - | (49 | ) | ||||||||||
| Capital gain from sale of subsidiary | - | (34 | ) | - | ||||||||||
| Capital loss from sale of equipment | 1 | - | 5 | |||||||||||
| 1 | (8 | ) | 961 | |||||||||||
| d. | Finance income: | |||||||||||||
| Interest income on bank deposits | (1 | ) | (1 | ) | - | |||||||||
| Exchange rate differences | - | - | (5 | ) | ||||||||||
| (1 | ) | (1 | ) | (5 | ) | |||||||||
| e. | Finance expenses: | |||||||||||||
| Finance expenses from interest and commissions | 5 | 1 | - | |||||||||||
| Finance expenses from liability to the INATI | - | - | 9 | |||||||||||
| Exchange rate differences | 486 | 7 | - | |||||||||||
| $ | 491 | $ | 8 | $ | 9 | |||||||||